-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 95 percent of adults worldwide areinfected with theEB virusInfections are usually asymptomatic, and the virus can lurk in small groups of lymphocytes throughout the patient's life cycleIn some cases, such cells may undergo a malignant transformation and becomelymphomaIn addition to lymphoma, the EB virus is also associated with a variety of solid tumors, including nasopharyngeal cancer andstomach cancerViracta Therapeutics, a pharmaceutical company that specializes in virus-related malignanciesthe, announced today that its combination of nanatinostat and valganciclovir has been named an orphan drug by the U.SFood and Drug AdministrationAdministration(
FDA) to treat EB-related T-cell lymphoma The combination of nanatinostat and valganciclovir has previously been awarded the title of orphan medicine for the treatment of post-transplant lymphocytic disease, plasma cell lymphoma and aveh immunity oocyte T-cell lymphoma Nanatinostat (VRx-3996) is an oral histone deacetyl enzyme (HDAC) inhibitor developed by Viracta Nanatinostat is selective in specific type of work for class I HDAC, which is key to inducing latent viral genes in EB virus-related malignancies